DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Conditions:   Malignancy;   Malignant Neoplasm;   Lymphoproliferative Disorders;   Neoplasms by Histologic Type;   Neoplasms by Site;   Cancer;   Colorectal Neoplasms;   Endometrial Neoplasms;   Melanoma Intervention:   Drug: Atezolizumab Sponsors:   Cancer Research UK;   University of Manchester;   University of Birmingham;   Royal Marsden NHS Foundation Trust;   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials